We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva has vowed to defend patents protecting its blockbuster multiple sclerosis (MS) treatment Copaxone after the FDA accepted Momenta and Sandoz’s ANDA for a generic version of it.